218 related articles for article (PubMed ID: 34482382)
1. Non-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation.
Xia J; Zhang J; Wang L; Liu H; Wang J; Liu J; Liu Z; Zhu Y; Xu Y; Yang W; Yu Y
Cell Death Dis; 2021 Sep; 12(9):833. PubMed ID: 34482382
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.
Ji G; He S; Huang C; Gong Y; Li X; Zhou L
Int J Biol Sci; 2021; 17(7):1613-1628. PubMed ID: 33994848
[TBL] [Abstract][Full Text] [Related]
3. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.
Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C
Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Monga J; Subramani D; Bharathan A; Ghosh J
Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
[TBL] [Abstract][Full Text] [Related]
6. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.
Zhang L; Blackwell K; Workman LM; Chen S; Pope MR; Janz S; Habelhah H
Mol Cell Biol; 2015 Oct; 35(19):3324-38. PubMed ID: 26195820
[TBL] [Abstract][Full Text] [Related]
7. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract][Full Text] [Related]
8. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.
Monga J; Adrianto I; Rogers C; Gadgeel S; Chitale D; Alumkal JJ; Beltran H; Zoubeidi A; Ghosh J
J Biol Chem; 2022 Feb; 298(2):101556. PubMed ID: 34973338
[TBL] [Abstract][Full Text] [Related]
9. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.
Chang CY; Chen JT; Chen TH; Chen RM
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235203
[TBL] [Abstract][Full Text] [Related]
13. Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-κB Activation and Cell Survival.
Horn S; Hughes MA; Schilling R; Sticht C; Tenev T; Ploesser M; Meier P; Sprick MR; MacFarlane M; Leverkus M
Cell Rep; 2017 Apr; 19(4):785-797. PubMed ID: 28445729
[TBL] [Abstract][Full Text] [Related]
14. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
Ruan H; Bao L; Tao Z; Chen K
Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
[TBL] [Abstract][Full Text] [Related]
15. Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.
Tsao CW; Li JS; Lin YW; Wu ST; Cha TL; Liu CY
Sci Rep; 2021 Jan; 11(1):1239. PubMed ID: 33441906
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.
McCann C; Crawford N; Majkut J; Holohan C; Armstrong CWD; Maxwell PJ; Ong CW; LaBonte MJ; McDade SS; Waugh DJ; Longley DB
Cell Death Dis; 2018 Oct; 9(11):1081. PubMed ID: 30349042
[TBL] [Abstract][Full Text] [Related]
18. NF-κB regulates caspase-4 expression and sensitizes neuroblastoma cells to Fas-induced apoptosis.
Yang HJ; Wang M; Wang L; Cheng BF; Lin XY; Feng ZW
PLoS One; 2015; 10(2):e0117953. PubMed ID: 25695505
[TBL] [Abstract][Full Text] [Related]
19. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Nadiminty N; Tummala R; Liu C; Yang J; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2013 Aug; 12(8):1629-37. PubMed ID: 23699654
[TBL] [Abstract][Full Text] [Related]
20. Activation of NF-kappaB by FADD, Casper, and caspase-8.
Hu WH; Johnson H; Shu HB
J Biol Chem; 2000 Apr; 275(15):10838-44. PubMed ID: 10753878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
